Atoosa Keshavarzi, Ali Asi Shirazi, Rastislav Korfanta, Nina Královič, Mária Klacsová, Juan Carlos Martínez, José Teixeira, Sophie Combet, Daniela Uhríková
The clinical benefits of using exogenous pulmonary surfactant (EPS) as a carrier of budesonide (BUD), a non-halogenated corticosteroid with a broad anti-inflammatory effect, have been established. Using various experimental techniques (differential scanning calorimetry DSC, small- and wide- angle X-ray scattering SAXS/WAXS, small- angle neutron scattering SANS, fluorescence spectroscopy, dynamic light scattering DLS, and zeta potential), we investigated the effect of BUD on the thermodynamics and structure of the clinically used EPS, Curosurf® ...
March 4, 2024: International Journal of Molecular Sciences